Personalized Organoid-Chip Model For Drug Testing in Pancreatic Cancer
用于胰腺癌药物测试的个性化类器官芯片模型
基本信息
- 批准号:10570699
- 负责人:
- 金额:$ 22.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAdjuvantAntineoplastic AgentsBasic ScienceBiological AssayCD8-Positive T-LymphocytesCancer BiologyCancer PatientCancerousCell CommunicationCell Differentiation processCellsCharacteristicsClinicalClinical TrialsComplexDecision MakingDevicesDisease ProgressionDrug Delivery SystemsDrug ModelingsDrug TargetingElementsEndotheliumEnvironmentEpitheliumFailureFibroblastsFibrosisGenesGoalsHumanImmuneImmunotherapyIndividualInterruptionMacrophageMalignant NeoplasmsMalignant neoplasm of pancreasModelingMolecularMolecular ProfilingOrganOrganoidsOutcomePancreatic Ductal AdenocarcinomaPathogenicityPathologyPathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhenotypePrediction of Response to TherapyResistanceRoleSeriesSolid NeoplasmSourceSurvival RateSystemT-LymphocyteTechnologyTestingTherapeuticTissuesTumor ImmunityTumor PromotionVascularizationcancer immunotherapycancer therapycancer typecell typechemotherapycohortconventional therapydesigndrug developmentdrug efficacydrug testingexperimental studyfunctional outcomesimprovedin vivoindividual responseindividualized medicineinnovationmalignant breast neoplasmmicrofluidic technologymolecular modelingnext generationnovelnovel therapeuticsorgan on a chippancreatic cancer modelpancreatic stellate cellpatient subsetspersonalized medicinepersonalized strategiespre-clinicalprotein expressionreal time monitoringresearch and developmentresponsestellate cellstem cellstargeted treatmenttherapy resistanttreatment responsetumortumor behaviortumor microenvironmenttumor progression
项目摘要
ABSTRACT
In order to improve cancer patient outcomes, the next generation of cancer therapeutics should combine
targeted treatments with the ability to predict the likelihood of an individual’s tumor to benefit from a given
treatment. The focus of this project is on advancing a personalized platform based on the individual’s tumor
behavior which is determined not only by the cancerous epithelium but the entire tumor microenvironment
(TME). The role of TME in disease progression or even therapeutic drug response is well established in variety
of cancers with poor outcome including pancreatic ductal adenocarcinoma (PDA) with a five year survival rate
of less than 10%. Here, combining 3D patient-derived organoids (PDO) and microfluidic technologies, we will
develop a novel tumor-chip device with the potential to generate individualized treatment response predictions
ex vivo. In Aim 1, using multiple tissue and functional read outs we will show that our multicellular platform
recapitulates the tumor and its microenvironment. In Aim 2, we will show the utility of our system as an
individualized ex vivo platform to functionally characterize the tumor response to conventional and novel
therapies. Our long-term goal is to optimize patient-specific ex vivo drug response assay technology such that
it may be used to rapidly, accurately, and reliably inform individualized treatment decisions. As a proof of
concept, the project involves developing a personalized pancreatic cancer model; however this technology can
be extended to other solid tumor types with rich TME (i.e., breast cancer) to improve molecular and/or cellular
characterizations of cancer biology and therapeutics.
摘要
为了改善癌症患者的治疗效果,下一代癌症治疗剂应结合联合收割机
有针对性的治疗,能够预测一个人的肿瘤的可能性,以受益于给定的
治疗该项目的重点是推进基于个体肿瘤的个性化平台
这不仅是由癌上皮细胞,但整个肿瘤微环境决定的行为
(TME)。TME在疾病进展或甚至治疗药物反应中的作用在各种研究中得到了很好的证实。
预后不良的癌症,包括胰腺导管腺癌(PDA),5年生存率
低于10%。在这里,结合3D患者源性类器官(PDO)和微流体技术,我们将
开发一种新的肿瘤芯片设备,有可能产生个性化的治疗反应预测
离体。在目标1中,使用多个组织和功能读数,我们将表明我们的多细胞平台
它概括了肿瘤及其微环境。在目标2中,我们将展示我们的系统作为
个体化离体平台,以功能性地表征肿瘤对常规和新型抗肿瘤药物的反应。
治疗我们的长期目标是优化患者特异性离体药物反应测定技术,
它可以用于快速、准确和可靠地告知个体化治疗决策。作为服务的证明
概念,该项目涉及开发个性化的胰腺癌模型;然而,这项技术可以
扩展到具有丰富TME的其他实体瘤类型(即,乳腺癌)以改善分子和/或细胞
癌症生物学和治疗学的表征。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Faraz Bishehsari其他文献
Faraz Bishehsari的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Faraz Bishehsari', 18)}}的其他基金
Development of a precision medicine platform for circadian based therapeutics in pancreatic cancer
开发基于昼夜节律的胰腺癌精准医学平台
- 批准号:
10707929 - 财政年份:2022
- 资助金额:
$ 22.88万 - 项目类别:
Development of a precision medicine platform for circadian based therapeutics in pancreatic cancer
开发基于昼夜节律的胰腺癌精准医学平台
- 批准号:
10477631 - 财政年份:2022
- 资助金额:
$ 22.88万 - 项目类别:
Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis
酒精诱发结肠癌中的异常进食时间和昼夜节律不同步
- 批准号:
10451641 - 财政年份:2018
- 资助金额:
$ 22.88万 - 项目类别:
Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis
酒精诱发结肠癌中的异常进食时间和昼夜节律不同步
- 批准号:
10166729 - 财政年份:2018
- 资助金额:
$ 22.88万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别: